Small cell carcinoma of the lung: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
| Caption = Lung small cell carcinoma. [[H&E stain]]. | | Caption = Lung small cell carcinoma. [[H&E stain]]. | ||
| Synonyms = | | Synonyms = | ||
| Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, | | Micro = stippled chromatin, high [[NC ratio]] with scant basophilic cytoplasm, typically small cells (~2x [[RBC]] diameter), +/-nuclear moulding, nuclei with smudgy appearance ([[Azzopardi phenomenon]]), necrosis, mitoses | ||
| Subtypes = histology: large cell neuroendocrine carcinoma (LCNEC); molecular subtypes: ASCL1, NEUROD1, POU2F3, YAP1 | | Subtypes = histology: large cell neuroendocrine carcinoma (LCNEC); molecular subtypes: ASCL1, NEUROD1, POU2F3, YAP1 | ||
| LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]] | | LMDDx = poorly differentiated [[adenocarcinoma of the lung]], [[atypical carcinoid]], [[lung carcinoid]], metastatic [[small cell carcinoma]], [[lymphoma]], other [[small round blue cell tumours]] (e.g [[Ewing sarcoma]], [[NUT carcinoma]]) | ||
| Stains = | | Stains = | ||
| IHC = chromogranin +ve, synaptophysin +ve, CD56 +ve, NSE +ve, TTF-1 +ve, Ki-67 (>50%) | | IHC = chromogranin +ve, synaptophysin +ve, CD56 +ve, NSE +ve, TTF-1 +ve, Ki-67 (>50%) | ||
| Line 115: | Line 115: | ||
! IHC grouping | ! IHC grouping | ||
! Prevalence | ! Prevalence | ||
! Other IHC | |||
! Notes | ! Notes | ||
|- | |- | ||
|ASCL1+ / NeuroD1- | |ASCL1 +ve / NeuroD1 -ve | ||
|41% | |41% | ||
|TTF-1 +ve | |||
| | | | ||
|- | |- | ||
|ASCL1+ / NeuroD1+ | |ASCL1 +ve / NeuroD1 +ve | ||
|37% | |37% | ||
|TTF-1 +ve | |||
| | | | ||
|- | |- | ||
|ASCL1- / NeuroD1+ | |ASCL1 -ve / NeuroD1 +ve | ||
|8% | |8% | ||
|TTF-1 +ve | |||
| | | | ||
|- | |- | ||
|ASCL1- / NeuroD1- | |ASCL1 -ve / NeuroD1 -ve | ||
|14% | |14% | ||
|includes all POU2F3 cases which are ~9% of small cell carcinoma | |TTF-1 -ve | ||
|includes all POU2F3 +ve cases which are ~9% of small cell carcinoma | |||
|} | |} | ||